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SUMMARY
We describe the rate of incidence of Clostridium difficile-associated diarrhea (CDAD) in hematologic and patients undergone 
stem cell transplant (HSCT) at HC-FMUSP, from January 2007 to June 2011, using two denominators 1,000 patient and 1,000 days of 
neutropenia and the risk factors associated with the severe form of the disease and death. The ELISA method (Ridascreen-Biopharm, 
Germany) for the detections of toxins A/B was used to identify C. difficile. A multivariate analysis was performed to evaluate potential 
factors associated with severe CDAD and death within 14 days after the diagnosis of CDAD, using multiple logistic regression. Sixty-
six episodes were identified in 64 patients among 439 patients with diarrhea during the study period. CDA rate of incidence varied 
from 0.78 to 5.45 per 1,000 days of neutropenia and from 0.65 to 5.45 per 1,000 patient-days. The most common underlying disease 
was acute myeloid leukemia 30/64 (44%), 32/64 (46%) patients were neutropenic, 31/64 (45%) undergone allogeneic HSCT, 61/64 
(88%) had previously used antibiotics and 9/64 (13%) have severe CDAD. Most of the patients (89%) received treatment with oral 
metronidazole and 19/64 (26%) died. The independent risk factors associated with death were the severe form of CDAD, and use of 
linezolid.
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INTRODUCTION
Diarrhea is a common complication in patients who receive high 
doses of chemotherapy and in those undergone hematopoietic stem 
cell transplant (HSCT)3,13,21,23. Clostridium difficile has frequently been 
identified as cause of infectious diarrhea in hospital setting. Its incidence 
rates range from 4.8% to 9% in patients with acute myelogenous 
leukemia, from 4.9% to 7.5% in patients undergoing autologous and from 
14% to 30.4% in those undergoing allogeneic HSCT1,2,4,16,25. The frequent 
and prolonged use of antibiotics may increase even further the risk of 
C. difficile associated diarrhea (CDAD) in this population of patients23. 
Despite these risk factors being frequent in these patients, data of CDAD 
in haematologic patients are still scarce.
Therefore, studies that evaluate CDAD in this population of patients 
can be useful for delineating measures of control and prevention of 
dissemination of this agent.
OBJECTIVE
To describe the rate of incidence and treatment of CDAD in 
hematological and HSCT patients, and the risk factors associated with 
the severe form of the CDAD and death.
PATIENTS, MATERIAL, METHODS
Study setting: The hematology and bone marrow transplant wards 
have 20 beds, are located in the Central Institute of Hospital das Clinicas 
(ICHC – FMUSP), Brazil, a teaching hospital with 1,000 beds. The bone 
marrow ward has four rooms, totalizing eight beds, and one room for 
contact isolation. All suspected cases of CDAD were placed in a contact 
isolation room, and remained in isolation until resolution of symptoms.
Study design: It is a retrospective study, the clinical records of all 
the patients in the hematology and bone marrow transplant wards during 
the period from January 2007 to June 2011 that performed C. difficile 
toxins A/B were analyzed. Its study has been approved by the Hospital 
das Clinicas of University of São Paulo, Brazil, Ethics Committee.
Definition of a case of CDAD: Hematologic patient with diarrhea 
(three or more soft stools within 24 hours) and positive for toxins A/B, 
who received treatment for CDAD.
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Patients considered suspect were those who presented diarrhea and 
collected stools for the investigation of C. difficile toxins A/B.
Definition of severe disease: Patients presented with one or more 
of the following variables during the treatment of diarrhea: hypotension; 
shock, renal insufficiency (50% decreases in creatinine clearance), toxic 
megacolon; colectomy and death within up to 30 days of onset of clinical 
symptoms.
The incidence rates of CDAD were calculated using two 
denominators: 1,000 patient-days and 1,000 days of neutropenia.
Data collection: Data on the number of hematologic and HSCT 
patients who sent stool samples for toxins A/B investigation were 
provided by the Information and Hospital Management System (SIGH) 
of the Central Laboratory Department (DLC). Data with positive toxins 
A/B are stored in a database of the sub-commission of hospital infection 
control of the Central Institute of Hospital das Clinicas of University of 
São Paulo.
The following variables were evaluated: age, gender, underlying 
disease, type of autologous and allogeneic HSCT (related or unrelated), 
time of transplant until the onset of diarrhea, presence of neutropenia, 
neutropenia/day, mucositis (presence and degree of mucositis as per 
the WHO), graft versus host disease (GVHD), the antimicrobials used; 
immunosuppressant drugs and chemotherapy, prior use of an antibiotic 
(up until 30 days before the development of diarrhea), and if the patients 
stayed in the same room. Other causes of diarrhea (rotavirus, parasites, 
GVHD, or neutropenic colitis), reactivation of cytomegalovirus (PCR and/
or antigenemia positive in the blood), Vancomycin-Resistant Enterococci 
(VRE) colonization, performance of colonoscopy, and presence of 
pseudomembrane. The surveillance culture for identification of (VRE) 
is carried out weekly by rectal swab and/or stool culture and seeded in 
a selective medium with 6 µg/mL of vancomycin from all patients in 
the hematology and bone marrow transplant wards. Antigenemia and 
real-time polymerase chain reaction for Cytomegalovirus are performed 
twice a week in all HSCT patients from the moment of marrow infusion 
to one hundred days after transplantation.
The room and period of inpatient stay of the patients were evaluated 
to verify how many patients were contacts of a positive case of C. difficile, 
and how many developed CDAD.
The following data relative to the treatment of CDAD were evaluated: 
type of antibiotic used (oral/venous metronidazole or vancomycin), 
dosage, time, change in clinical picture. Clinical response in seven 
days: symptom resolution; partial response (50% reduction in frequency 
of diarrhea episodes); no response; worsening (megacolon and/or 
perforation). Response at the end of treatment (last day of antibiotic 
specific for the treatment of CDAD) was evaluated: symptom resolution; 
partial response (50% reduction in the frequency of diarrhea episodes); 
no response; worsening; and if there is relapse within 30 days.
Deaths during the treatment of CDAD were evaluated, considering 
death until 14 days after the onset of treatment, and death during 
hospitalization.
Microbiological procedures: The ELISA method (Ridascreen-
Biopharm, Germany) was used to identify C. difficile toxins A/B.
Statistical analysis: The information was filed in a computerized 
database utilizing the Epi Info 6.04b program. A descriptive analysis 
was made of patient characteristics; continuous variables were expressed 
as mean, standard deviation, median, and interval, and compared by 
Wilcoxon’s test, and the categorical variables by Chi-squared and Fisher’s 
Exact tests. The outcomes studied were severity of the clinical symptoms 
and death within 14 days after the diagnosis of CDAD. The level of 
significance adopted for comparison of the variables in the bivariate was 
the value of p < 0.05. A multivariate analysis was performed to evaluate 
potential factors associated with severe CDAD and death within 14 days 
after the diagnosis of CDAD, using multiple logistic regression. The 
variables with p < 0.10 in the bivariate analysis and biological plausibility 
were tested in the multivariate analysis by stepwise forward. Chi-squared 
for tendency was used to evaluate the distribution of suspected and 
confirmed cases of CDAD and the incidence of cases confirmed during 
the study period from 2007 to 2011.
RESULTS
During the study period (January 2007 to June 2011), 983 hematology 
and 1136 HSCT inpatients were followed, a total of 25,312 patients-day 
and 9,902 days of neutropenia. Four hundred thirty-nine patients with 
diarrhea performed C. difficile toxins A/B tests. A total of 66 episodes of 
CDAD in 64 patients were positive and the records of these patients were 
reviewed. During the study period the cumulative incidence of CDAD 
was 3.1%. The rate of incidence of CDAD per 1,000 days of neutropenia 
varied from 0.78 to 5.45 and per 1,000 patient-days varied from 0.78 to 
10.24 during the study period. The Chi-squared for tendency showed that 
the number of suspected cases of CDAD (p = 0.4180) and severe form 
of diseases (p = 0.69) remained stable, in contrast with the increase in 
number of confirmed cases (p = 0.0006).
The clinical and demographic data of 64 patients with CDAD over 
the study period are shown on Table 1. Most (68%) of the patients were 
males, the age varied from 12 to 65 years old, and the mean age was 38.9; 
median 38.5 and mode 38.0 years old. The most common underlying 
disease was acute myeloid leukemia 30/64 (44%), and of these, 32/64 
(46%) were neutropenic, 31/64 (45%) undergone allogeneic HSCT, and 
61/64 (88%) of the patients had received antibiotics. C. difficile-associated 
diarrhea was more frequent in HSCT patients 46/64 (69%), of which 
31/46 (67%) were allogeneic transplants, than in hematologic patients 
18/64 (31%). The overall mortality was 24/64 (35%) and the mortality 
within 14 days of diagnosis was 19/64 (26%).
At the onset of diarrhea, the use of metronidazole was introduced 
after collecting the stool before the result of test for CDAD. The average 
number of days to perform the toxins test until the use of metronidazole 
was one day. Most (89%) of the patients were treated with metronidazole; 
four patients initiated oral treatment and then switched to intravenous; 
three patients were hospitalized in ICU and received metronidazole 
intravenously. After seven days of treatment with metronidazole, 37% 
of the patients showed a partial response, and 57% had symptoms 
resolution with 14 days of treatment. Three patients experienced 
relapse of the disease in less than 30 days. Of the 43% that did not show 
symptom resolution at the end of treatment (14 days), 24% died during 
hospitalization, 3% had coinfection, and 3% GVHD. The severe form of 
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the disease was found in only nine patients (14%), and all of them died; 
seven of them (80%) died within 14 days.
The bivariate analysis of the risk factors associated with the severe 
form of CDAD identified allogeneic HSCT, use of glycopeptides and 
cyclophosphamide as risk factors; however, the multivariate analysis did 
not identify any independent risk factor (Table 2).
The bivariate analysis of risk factors associated with death within 
14 days of the diagnosis of CDAD identified allogeneic transplant, 
severe form of the disease, linezolid and cyclophosphamide use and 
hospitalization as risk factors for death and lymphoma as protector. Two 
models of multivariate analysis were conducted to evaluate the death 
outcome, one with and the other without the age variable. In spite of 
not showing p < 0.1, age was included in the model because it had been 
described in various studies as a risk factor associated with mortality. 
On the other hand, ICU stay is a collinear variable of severity and was 
not included in the model (Table 3). 
DISCUSSION
During the period studied, the cumulative incidence of CDAD was 
3.1%, it rose without increasing in clinical suspicion and severe forms 
of diseases. These data are interesting and in accordance with many 
countries that have been showing the increasing in CDAD incidence. 
Different denominators have been used to calculate the incidence of 
infection by C. difficile1,2,3,4,10,16,25. The guideline of CDAD recommends 
the using as denominator 100 thousand patients11. In our study, we opted 
to use two denominators, namely, patient-days and days of neutropenia, 
because of the population studied. The presence and duration of the 
neutropenia are important risk factors for healthcare associated infections 
in this population of patients, and has been used as a denominator by 
other authors14,17. One limitation of our study is precisely the method 
“ELISA” used to diagnosis infection by C. difficile that is not very 
sensitive, sensitivity varying from 63 to 94%11.
We identified more CDAD in HSCT patients (69%), of which 31/46 
(67%) were allogeneic transplants, than in hematologic patients (31%). 
The mean of days of HSCT until the onset of diarrhea was 11 days in 
the present study. TOMBLYN et al. 200223 described a mean of one day 
after HSCT (varied from three to seven days). A greater frequency of 
C. difficile infection is expected during the first month after HSCT, a 
period when the patients are exposed to chemotherapy and antibiotics, 
important risk factors associated with this agent. Nine of sixty-four 
(13%) patients presented the severe form of CDAD, higher than the 5% 
previously described by WILLENS et al. 201227.
Previous use of antimicrobials is cited by various authors1,2,4 as an 
important risk factor for the development of CDAD. Most of the patients 
of this study received antibiotics before the onset of the diarrhea; the most 
commonly used was carbapenem. However, 12% did not; this finding 
may be a result of crossover transmission of the agent, or exposure to 
other risk factors.
New drugs to treat CDAD are now available18, despite this, data 
have been showing that metronidazole is a safe option to treat C. 
difficile infection in hematologic and HCST patients, with few cases of 
relapse13,16,27. In our study 57% of patients had symptoms ending with 
Table 1
Demographic and clinical data of hematologic and HSCT patients with 
diarrhea due to C. difficile, HC-FMUSP, 2007 to June 2011
N: 64 patients %
Age Mean age 38.5 
(12-65 years old)
Underlying Disease  
Aplasia 
Acute Lymphoid Leukemia  
Acute Myeloid Leukemia 
Chronic Myeloid Leukemia 
Lymphoma 
Multiple Myeloma  
Others 
Hospitalization Unit 
Hematology
Bone Marrow
 
3 
8 
30 
4 
9 
5 
7 
 
23
46
 
4 
12 
44 
6 
13 
7 
10 
 
33
67
Type of HSCT
Allogeneic
Unrelated 
Autologous 
Days after HSCT until diarrhea
Days of hospitalization until diarrhea 
Days of neutropenia until diarrhea 
Prior use of antibiotic 
Sulfamethoxazole+trimethoprim 
Carbapenems 
Cefepime 
Colistin 
Linezolid 
Quinolone 
Piperacillin/Tazobactam
Hospitalization in the same room with case 
positive for C. difficile
GVHD
ERV
31
4
14
Mean 11 (1-407)
Mean 9 (1-105) 
Mean 13 (3-36) 
61 
20 
37 
18 
13 
7 
9 
16
18
17
30
45
6
20
 
 
88 
29 
54 
26 
19 
10 
13 
23
26
25
44
Co-infection
CMV
Parasites
Severe forms
Mortality within 14 days 
General mortality 
Neutropenia
14
3
9
19
24 
32
20
5
13
26
35 
46
Days of hospitalization. until diarrhea, 
mean (variation)
Days of diarrhea until toxin collection 
(variation)
Toxin collection until initiation of treatment 
(variation)
Megacolon
Severe forms
Mean 9 (1-105 days)
Mean 2 (1-20 days)
Mean 1(0-20 days)
2
9
3
13
TREATMENT
Metronidazole IV
Metronidazole PO
Vancomycin IV
Vancomycin PO
Partial Response 
End of treatment 
Relapse
Patients did not finish treatment
7
61
0
0
24*
39•
3
20
10
88
37
57.4
4.3
24.6
GVHD: Graft versus host disease; VRE: Vancomycin-resistant enterococci, CMV: 
cytomegalovirus; ATB: antibiotic. *number of patients with partial response in 
the first 7 days of treatment, •number of patients who finished treatment and 
experienced symptom resolution, IV: intravenous; PO: oral
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14 days of treatment. Coinfection and the presence o GVHD may be 
the reasons for the non-resolution of symptoms. The literature shows 
that, until the moment, there is a lack of association of resistance to 
metronidazole with non-response or relapse5,6,18,19,22,26. In Brazil, two 
studies that evaluated C. difficile susceptibility to metronidazole showed 
that all strains were susceptible to metronidazole and did not identified 
ribotype 027 in the country8,9. In the present study, it was not possible 
to evaluate the impact of sensitivity of C. difficile isolates on therapeutic 
response.
Quinolone is frequently used as bacterial prophylaxis during 
periods of neutropenia; it has been recently associated with outbreaks 
of community infection and severe form of CDAD4,11. Therefore, we 
assessed the association of previous use of quinolone with severe 
forms of disease. However, bivariate analysis showed that the risk 
factors for the severe form of CDAD were allogeneic HSCT, and use of 
glycopeptides and cyclophosphamide, risk factors directly associated 
with the severity of the patient. Sharing the same room was a protective 
factor for the development of the severe form of CDAD. Nevertheless, in 
the multivariate analysis it was not possible to identify any independent 
risk factor associated with the severe form of CDAD, probably due to 
the size of the population evaluated.
The mortality in the present study was not greater than previously 
described1,10. Overall mortality was 37.5%, 34% in hematologic and 66% 
in HSCT patients, 58% of them allogeneic transplanted, and death within 
Table 2
Risk factors associated with the severe form of diarrhea caused by C. difficile in hematologic and HSCT patients
Variable
Severe form Bivariate analysis
Yes 
N = 9
No 
N = 57 OR (95% CI) p value*
Age 21-57 (39) 0.5
Male 5(11%) 39(89%) 0.6(0.15-3.1) 0.41
Underlying disease
Lymphoma 0(0) 9(100%) 0 0.26
AML 4(13%) 26(87%) 1(0.22-4.5) 0.61
ALL 2(25%) 6(75%) 2.5(0.3-14.9) 0.27
BML 1(33%) 3(67%) 0 0.43
Medullary aplasia 0(0) 3(100%) 2.3(0-24.8) 0.65
Multiple myeloma 0(0) 5(100%) 0 0.48
Allogeneic HSCT 7(23%) 24(77%) 5.1(1-38.6) 0.03
Autologous HSCT 0(0) 14(100%) 0 0.11
Prior use
Quinolone 2(22%) 7(78%) 2.1(0.25-12.1) 0.33
Sulfamethoxole +trimethoprim 1(5%) 19(95%) 0.27(0.01-1.88) 0.19
Cefepime 1(6%) 17(94%) 0.32(0.01-2.22) 0.25
Carbapenems 4(11%) 33(89%) 0.65(0.14-2.84) 0.4
Colistin 1(8%) 12(92%) 0.5(0.02-3.61) 0.45
Glycopeptides 2(5%) 35(95%) 0.2(0.02-1.02) 0.04
Piperacillin-Tazobactam 2(12%) 14(88%) 0.9(0.12-4.8) 0.65
VRE 2(7%) 28(93%) 0.3(0.04-1.62) 0.15
CMV 2(14%) 12(88%) 1.1(0.14-5.93) 0.58
GVHD 3(18%) 14(82%) 1.6(0.29-7.46) 0.38
Days hospitalized for diarrhea, mean(variation) 1(1-22) 10(1-105) 0.16
Days for diarrhea collection toxins, mean  1(1-20) 1(1-18) 0.23
Collection of toxins/onset of treatment, mean 2(1-6) 1(0-20) 0.94
Chemotherapy 2(6%) 30(94%) 0.29(0.03-1.42) 0.11
Cyclophosphamide 4(31%) 9(69%) 4.3(0.89-20.85) 0.05
Steroids 2(29%) 5(71%) 3(0.35-19.13) 0.22
Immunosuppression 7(15%) 41(85%) 1.6(0.32-12.24) 0.44
Same room as a positive case for C. difficile 0(0) 18(100%) 0 0.05
GVHD: Graft versus host disease; AML: Acute Myeloid Leukemia, ALL; Acute Lymphoid Leukemia, CML: Chronic Myeloid Leukemia; HSCT VRE: Vancomycin-
resistant Enterococci; CMV: cytomegalovirus.
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14 days was 19/64 (26%). On the other hand, the mortality among the 
severe form of CDAD was unusually high, 80% of patients died within 
14 days. The severe forms of CDAD were treated with metronidazole in 
our study what can have been impacted in the high mortality. The IDSA 
guideline recommends the use of vancomycin orally for severe forms of 
CDAD, but this presentation is not yet available in Brazil11.
Age is one of the primary risk factors associated with death in patients 
with CDAD20. The mean age of the patients studied in our cases was 
38.9 years old, a young population probably due to the type of patient 
evaluated, 75% of patients of less than 50 years old and three (5%) 
patients of 12 years old. Other risk factors described as associated with 
death in hematologic patients are colonization by VRE 28, GVHD12 and 
severe form of diseases15,16. We found that the severe form of diseases, 
ICU stay, allogeneic HSCT, and use of cyclophosphamide and linezolid 
were risk factors for death within 14 days, and lymphoma was protector. 
Tabela 3
Multivariate analysis of risk factors associated with the severe form of diarrhea 
caused by C. difficile in hematologic and HSCT patients
Variable
Multivariate analysis
OR (95% CI) p value**
Allogeneic HSCT 2.5(0.2-23.9) 0.40
Glycopeptides 0.25(0.03-1.7) 0.16
Cyclophosphamide 4.9(0.5-43) 0.14
Same room as a posi-
tive case for C. difficile
0(0-1.0) 0.97
GVHD: Graft versus host disease; AML: Acute Myeloid Leukemia, ALL; 
Acute Lymphoid Leukemia, CML: Chronic Myeloid Leukemia; HSCT VRE: 
Vancomycin-resistant Enterococci; CMV: cytomegalovirus.
Table 4
Bivariate analysis of risk factors associated with death within 14 days of diagnosis of diarrhea by C. difficile in hematologic and HSCT patients
Variable Death in 14 days N = 19
Survival 
N = 45
Bivariate Analysis
OR (95% CI) p value
Age, mean years old 39(19-59) 38(12-65) 0.76
Gender 
Male 13(29%) 31(71%) 1.3(0.43-4.35) 0.41
Underlying disease 
Lymphoma 0(0) 9(100%) 0 0.04
AML 9(30%) 21(70%) 1.2(0.41-3.66) 0.44
ALL 3(37%) 5(63%) 1.6(0.29-8) 0.38
CML 0(0) 4(100%) 0 0.26
Medullary aplasia 1(33%) 2(67%) 1.3(0-18.36) 0.62
Multiple myeloma 1(20%) 4(80%) 0.6(0.02-5.52) 0.57
Allogeneic HSCT 12(39%) 19(61%) 2.7(0.92-8.67) 0.05
Autologous HSCT 2(14%) 12(86%) 0.3(0.05-1.7) 0.18
Prior use antibiotic
Quinolone 3(38%) 5(62%) 0.5(0.11-3.42) 0.26
Sulfa+trimethoprim 7(35%) 13(65%) 1.6(0.51-5.15) 0.27
Cefepime 5(28%) 13(72%) 1(0.3-3.37) 0.60
Carbapenem 13(35%) 24(65%) 2.3(0.76-7.15) 0.10
Colistin 6(46%) 7(54%) 2.8(0.8-9.94) 0.09
Glycopeptides 10(27%) 27(73%) 0.9(0.32-2.72) 0.56
Linezolid 4(57%) 3(43%) 4.1(0.83-20.8) 0.08
Piperacillin/Tazobactam 3(19%) 13(81) 0.5(0.13-2.13) 0.28
Febrile neutropenia 7(22%) 25(78%) 0.5(0.18-1.74) 0.24
CMV 4(29%) 10(71%) 1(0.25-3.89) 0.58
VRE 6(20%) 24(80%) 0.5(0.15-1.53) 0.16
Other parasites 0(0) 5(100%) 0 0.18
Severe form 7(79%) 2(22%) 13.2(2.6-103.59) 0.001
Immunosuppressor 16(33%) 32(67%) 2.9(0.8-14.22) 0.08
Chemotherapy 7(22%) 25(78%) 0.5(0.18-1.74) 0.24
Steroids 3(43%) 4(57%) 2.1(0.36-11.39) 0.29
Cyclophosphamide 6(46%) 7(54%) 3(0.83-11.37) 0.09
ICU stay 11(52%) 10(48%) 5.3(1.69-17.63) 0.003
AML: Acute Myeloid Leukemia; ALL: Acute Lymphoid Leukemia; CML: Chronic Myeloid Leukemia; HSCT: hematopoietic stem cells transplant; VRE: Vancomycin-
resistant enterococci; CMV: cytomegalovirus; ICU: Intensive Care Unit.
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Table 5
Mutivariate analysis of risk factors associated with death within 14 days of 
diagnosis of diarrhea by C. difficile in hematologic and HSCT patients 
Variable
Multivariate Analysis
OR (95% CI) p value
Lymphoma 0 (0.0-1.0) 0.96
Allogeneic HSCT 2.14 (0.65-7.21) 0.22
Linezolid 5.02(1-25.0) 0.050
Severe form 8.90 (1.92-41.0) 0.015
Cyclophosphamide 2.513(0.61-10.0) 0.19
No patient with lymphoma died. In the multivariate analysis, however, 
the variables that remained as independent risk factors for death were 
severe form of the disease, and the use of linezolid. The risk factors 
identified in the present study are merely a marker of severity. VRE has 
been previously described as risk factor for CDAD; however, it was not 
identified as risk factor in our study. On the other hand, linezolid that 
has been used in our hospital to treat patients colonized by VRE, with 
persistent febrile neutropenia, or in sepsis and septic shock was a risk 
factor, unlike two previous studies that showed a potential benefit of 
linezolid in CDAD, an “in vitro” study that showed action of linezolid 
against C. difficile using a gut model and a epidemiologic study that 
demonstrated that linezolid protected patients with ventilator-associated 
pneumonia to develop CDAD7,24.
CONCLUSIONS
The incidence of CDAD increased significantly over the study period; 
however, the severe form of diseases remained stable. The independent 
risk factors associated with death in hematologic and HSCT patients in 
14-days of onset of CDAD were severe form of the disease, and the use 
of linezolid.
RESUMO
Diarreia por Clostridium difficile em pacientes hematológicos e 
transplantados de células tronco hematopoiéticas: fatores de risco 
da forma grave e morte
Descrevemos a taxa de incidência de diarreia associada a Clostridium 
difficile (CDAD) em pacientes hematológicos e submetidos a transplante 
de células-tronco hematopoiéticas (TCTH) internados no HC-FMUSP no 
período de janeiro de 2007 a junho de 2011 usando dois denominadores 
1.000 paciente e 1.000 dias de neutropenia e os fatores de risco associados 
à forma grave da doença e morte. O método de ELISA (Ridascreen-
Biopharm, Germany) de detecção de toxinas A/B foi utilizado para 
o diagnóstico de C. difficile. Análise multivariada usando regressão 
logística múltipla foi conduzida para avaliar os potenciais fatores de 
risco associados com forma grave de CDAD e morte em até 14 dias do 
diagnóstico. Sessenta e seis episódios foram identificados em 64 pacientes 
entre 439 pacientes que apresentaram diarreia durante o período do 
estudo. A taxa de incidência de CDAD variou de 0,78 a 5,45 por 1.000 
dias de neutropenia e de 0,65 para 5,45 por 1.000 pacientes-dias. A doença 
de base mais comum foi leucemia mielóide aguda 30/64(44%), 32/64 
(46%) pacientes estavam neutropênicos, 31/64 (45%) foram submetidos 
à TCTH alogênico, 61/64 (88%) usaram antibióticos previamente e 9/64 
(13%) apresentaram forma grave da doença. A maioria dos pacientes 
(89%) utilizou metronidazol oral no tratamento da CDAD e 19/64 (26%) 
evoluiram para óbito. Os fatores de risco independentes associados à 
morte foram forma grave da doença e uso de linezolida.
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